Abington Hematology Oncology Associates — Willow Grove, Pennsylvania

Abington Hematology Oncology Associates is a clinical research site located in Willow Grove, Pennsylvania, United States 19090.

Crixeo Clinical Trials Trust Score: 15/100 (FAILING). This profile has not yet been claimed by the site owner.

Abington Hematology Oncology Associates has participated in 6 clinical trials.

Therapeutic areas: First or Second Line HER2-negative Breast Cancer, Metastatic Disease Without Bone Metastasis, Breast Cancer.

Sponsors: Novartis Pharmaceuticals, Puma Biotechnology, Inc., Transgene.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Willow Grove

Browse all research sites in Pennsylvania · View every site in Willow Grove

Sponsor Feasibility Report

Trust Score: 15/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Abington Hematology Oncology Associates?

Abington Hematology Oncology Associates has a Crixeo Trust Score of 15/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Abington Hematology Oncology Associates conducted?

Abington Hematology Oncology Associates has 6 clinical trials on record. Their work covers First or Second Line HER2-negative Breast Cancer, Metastatic Disease Without Bone Metastasis, Breast Cancer.

Is Abington Hematology Oncology Associates accredited by Crixeo Clinical Trials?

Abington Hematology Oncology Associates has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Abington Hematology Oncology Associates?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.